[{"id":"937a6000-045b-4256-9396-e3a8e08cb006","acronym":"TUNINTIL","url":"https://clinicaltrials.gov/study/NCT04217473","created_at":"2021-01-18T20:31:59.350Z","updated_at":"2024-07-02T16:35:15.398Z","phase":"Phase 1","brief_title":"TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma","source_id_and_acronym":"NCT04217473 - TUNINTIL","lead_sponsor":"TILT Biotherapeutics Ltd.","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" TILs","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e igrelimogene litadenorepvec (TILT-123)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 12/12/2023","primary_completion_date":" 12/12/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-11"}]